About/Subscribe

Free Subscription to the Bipolar Network News newsletter

We publish a newsletter 4-6 times per year with the latest in bipolar research, both in print and via email.  To Subscribe:

For the email version: Please enter an email address here.

For the print version (US residents only): Please enter a complete postal address here.

Our mailing list is used only for the newsletter, and we do not share you information with anyone. If your address changes or you want to switch from the print to the email version of the newsletter, please email us at [protected email address] to update your information. Keeping us up-to-date with your current address will keep our costs down, and will ensure you get your newsletter on time.

About Bipolar Network News:

Some 6 million Americans suffer from bipolar disorder, and many struggle to manage this debilitating illness with the treatments currently available.

Bipolar Network News is both an online clearinghouse of information about mood disorders, and a quarterly print and email publication. We provide updates on the latest research about bipolar disorder, gleaned from abstracts, meetings, and pre-publication sources. We hope to shed light on emerging trends in research and treatment of bipolar illness in order to help educate patients, family members, interested laypeople, physicians, and other professionals in the field. The newsletter is available free of charge to all who request it.

Although the editors of the BNN have made every effort to report accurate information, much of the work referenced here is in abstract or pre-publication form, and may not have received proper review by the scientific community at this time. Patients should consult with their physicians about any treatment decisions.  Physicians should consult the published literature.

Editor-in-Chief: Robert M. Post, M.D.

Managing Editor: Moira McCauley

Dr. Post has consulted on behalf of or been a payed speaker for the following pharmaceutical companies: Abbott, AstraZeneca, Bristol-Myers Squibb, Glaxo-SmithKline, Jansen, and Pfizer.

The opinions expressed on this site and in the newsletter are solely those of the editors, and do not represent the views of any scientific entity or foundation.

To update your subscription, email [protected email address]. Note that we do not accept requests to subscribe friends or family members. Please have them contact us directly. For comments or questions about the content of this site or the print publication, email [protected email address].